TalkMed Group Limited

Equities

5G3

SG2G61000003

Healthcare Facilities & Services

Market Closed - Singapore S.E. Other stock markets 04:48:02 2024-04-25 am EDT			5-day change	1st Jan Change
0.415 ^SGD	+3.75%		+1.22%	+9.21%

Apr. 18	TalkMed Group Limited Approves Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2023	CI
Apr. 17	TalkMed Reaches Final Settlement in Mediation Related to Claims in Stem Med Stake Disposal	MT

Talkmed Group Limited Appoints Khoo Kei Siong as Alternate Director to Ang Peng Tiam, Effective January 1, 2024

November 10, 2023 at 04:57 am EST

TalkMed Group Limited announced the appointment of Dr Khoo Kei Siong as Alternate Director to Dr Ang Peng Tiam. Job Title: Chief Operating Officer and Alternate Director to Dr Ang Peng Tiam. Working Experience: Deputy Medical Director and Senior Consultant of Parkway Cancer Centre at Gleneagles Hospital.

Other directorships past: Academy of Medicine Singapore - CellVec Pte. Ltd. - Stem Med Pte. Ltd. Other directorships present: Singapore Cancer Centre Pte.

Ltd. - AYSUS Pte. Ltd. - TalkMed Vietnam Pte. Ltd. - Hong Kong Integrated Oncology Centre Holdings Limited - Hong Kong Integrated Oncology Centre Limited - TalkMed China Pte.

Ltd. - TalkMed Chongqing Pte. Ltd. - TalkMed Greater China Pte. Ltd. - TalkMed Hospital Management (Beijing) Co.

Ltd. - Beijing Yachuang Siwei Investment Management Co. Ltd. - Stem Med Indonesia Pte. Ltd. - BioCell Innovations Pte.

Ltd. Dr Khoo Kei Siong has been a director of the Company since 2013. Professional Qualifications: Bachelor of Medicine and Surgery University of Singapore Master of Medicine (Internal Medicine) National University of Singapore Certificate of Specialist Accreditation in Medical Oncology Ministry of Health (Singapore) Fellow Royal College of Physicians (Edinburg) Fellow Academy of Medicine (Singapore). Appointment date is January 1, 2024.

Latest news about TalkMed Group Limited

TalkMed Group Limited Approves Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2023	Apr. 18	CI
TalkMed Reaches Final Settlement in Mediation Related to Claims in Stem Med Stake Disposal	Apr. 16	MT
TalkMed Group Awards 1.1 Million New Shares	Mar. 13	MT
TalkMed's H2 Attributable Profit Falls on Wider Impairment Loss	Feb. 20	MT
Talkmed Group Limited Proposes Tax Exempt (One-Tier) Final Dividend for the Financial Year Ended 31 December 2023, Payable on 10 May 2024	Feb. 20	CI
TalkMed Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
TalkMed Group Grants Nearly 8 Million Share Awards Under Performance Share Plan	Dec. 20	MT
TalkMed Group Limited Announces Management Changes	Nov. 10	CI
TalkMed Group Limited Announces Re-Designation of Leong Ching Ching from Non-Executive Director to Independent Non-Executive Director and Appoints as Chairman of the Remuneration Committee, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Limited Announces Re-Designation of S. Chandra Das from Independent Non-Executive Director to Non-Independent Non-Executive Director, Effective 1 January 2024	Nov. 10	CI
TalkMed Group Limited Announces Re-Designation of Sitoh Yih Pin from Independent Non-Executive Director to Non-Independent Non-Executive Director, Effective 1 January 2024	Nov. 10	CI
Talkmed Group Limited Appoints Khoo Kei Siong as Alternate Director to Ang Peng Tiam, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Limited Appoints Dr Tan Khai Tong as Independent Non-Executive Director, Member of the Remuneration Committee, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Limited Appoints Peter Sim Swee Yam as Independent Non-Executive Director, Chairman of the Nominating Committee, Member of the Audit and Risk Committee, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Limited Appoints Lam Kok Shang as Independent Non-Executive Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee, Effective January 1, 2024	Nov. 10	CI
TalkMed Group Issues New Shares Upon Vesting of Share Awards	23-10-19	MT
TalkMed Group Issues New Shares Upon Vesting of Share Awards	23-10-17	MT
Singapore Stocks Track Global Gains to Close Higher; Delfi Shares Jump 3% on Higher H1 Profit, Revenue	23-08-08	MT
TalkMed Group's Attributable Profit Zooms 18% in H1	23-08-08	MT
TalkMed Group Limited Declares Tax Exempt (One-Tier) Interim Dividend for the Financial Year Ending 31 December 2023, Payable on 22 August 2023	23-08-07	CI
TalkMed Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-07	CI
TalkMed Group Establishes New Subsidiary for Cell, Gene Therapy	23-07-07	MT
TalkMed Group Limited Approves the Final One-Tier Tax-Exempt Dividend in Respect of 2022	23-05-16	CI
TalkMed Group Limited Proposes to Declare Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2022	23-04-04	CI
TalkMed Group Issues Nearly 2 Million Shares Upon Vesting of Share Awards	23-03-14	MT

Chart TalkMed Group Limited

Duration

Period

More charts

Company Profile

TalkMed Group Limited is a Singapore-based investment holding company. The Company provides medical oncology and palliative care healthcare services in Singapore. Its oncology specialist specializes in providing medical oncology services targeting various cancers, such as breast cancer, colon cancer, lung cancer, liver, biliary and pancreatic cancers, gastro-intestinal cancers, head and neck cancers, leukemia, hematology malignancies and brain cancer. The Company, through the Parkway Cancer Centre (PCC)-vehicle, offers a support system to cater to the psychosocial needs of its patients and their families. The Company, through Singapore Cancer Centre (SCC) and the Parkway Cancer Centre (PCC) vehicle, provides CANSCREEN, a screening program that provides screening for individuals at a higher risk of getting cancer. The Company offers cellular and gene therapy related products and services. It also operates in Vietnam, Hong Kong and the People's Republic of China.

Sector

Healthcare Facilities & Services

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
TALKMED GROUP LIMITED	+9.21%	404M
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
PURE HEALTH HOLDING	-31.75%	11.77B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
DAVITA INC.	+27.44%	11.71B

Other Healthcare Facilities & Services